The incidence of pleural infections in the United States has grown over the last 30 years. With a mortality rate between 10% and 20%, it is imperative that these patients are treated quickly and effectively. The goal of treatment is to drain infected fluid from the pleural space, which can be accomplished through the placement of a chest tube and fibrinolytics. Currently, there is little consensus on which fibrinolytic to use and what doses are needed for optimal treatment of thoracic empyemas, which is the presence of pus in the pleural cavity. This has led to a lack of standardized care among providers and institutions. The goal of this project was to determine if the use of intrapleural tPA and Dornase (DNase) is more effective than intrapleural tPA alone in treat patients with empyemas at Oregon Health & Science University (OHSU) hospital.